Skip to content

Flucytosine

Nucleoside Analog Antifungal — DERMATOLOGICALS

Also known as: 5-fluorocytosine, ancobon, ancotil, Ro 2-9915, Ro-2-9915

OfpFDA approvedATC D01AE21ATC J02AX01

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Flucytosine is an ofp drug in the Nucleoside Analog Antifungal class catalogued in DrugCentral. It was first approved by the FDA in 1971. DrugCentral lists 4 molecular targets, including HSP82, HTR2A and TMP1. Recorded indications include Candidal Urinary Tract Infection, Synergy for Candida Infection, Synergy for Cryptococcal Infection and Systemic Candidiasis Treatment Adjunct.

  • Approval status: ofp (first approved 1971 by the FDA).
  • Drug class: Nucleoside Analog Antifungal.
  • Molecular targets: HSP82, HTR2A, TMP1 and TMP1 (4 listed in DrugCentral).
  • Indications: Candidal Urinary Tract Infection, Synergy for Candida Infection, Synergy for Cryptococcal Infection, Systemic Candidiasis Treatment Adjunct and Systemic Cryptococcosis Treatment Adjunct.
  • ATC code: D01AE21 (Other antifungals for topical use).
  • Molecular formula: C4H4FN3O; molecular weight 129.09 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (5)

  • Candidal Urinary Tract Infection
  • Synergy for Candida Infection
  • Synergy for Cryptococcal Infection
  • Systemic Candidiasis Treatment Adjunct
  • Systemic Cryptococcosis Treatment Adjunct

Off-label uses (1)

  • Chromoblastomycosis

Contraindications (11)

  • Aplastic anemia due to drugs
  • Bone marrow depression
  • Breastfeeding (mother)
  • Disease of liver
  • Granulocytopenic disorder
  • Hypokalemia
  • Kidney disease
  • Leukopenia
  • Liver function tests abnormal
  • Radiation oncology AND/OR radiotherapy
  • Thrombocytopenic disorder

Mechanism & targets

Established pharmacologic classNucleoside Analog Antifungal

Molecular targets (4)

TargetGeneActionActivity
ATP-dependent molecular chaperone HSP82HSP82unknownEC50 6.15
5-hydroxytryptamine receptor 2AHTR2AunknownIC50 5.10
Thymidylate synthaseTMP1inhibitor—
Thymidylate synthaseTMP1inhibitor—

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
1971-11-26FDA—VALEANT

ATC classification

ATC codeTherapeutic hierarchy
D01AE21DERMATOLOGICALS › ANTIFUNGALS FOR DERMATOLOGICAL USE › ANTIFUNGALS FOR TOPICAL USE › Other antifungals for topical use
J02AX01ANTIINFECTIVES FOR SYSTEMIC USE › ANTIMYCOTICS FOR SYSTEMIC USE › ANTIMYCOTICS FOR SYSTEMIC USE › Other antimycotics for systemic use

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

  • Swissmedic label: DPYD · Testing Recommended

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Immune reconstitution inflammatory syndrome475.8
Drug ineffective418.5
Cryptococcosis173.6
Meningitis cryptococcal171.6
Disseminated cryptococcosis135.1
Renal impairment88.7
Acute kidney injury78.6
Drug ineffective for unapproved indication75.4
Ischaemic stroke66.5
Renal failure65.5
Intracranial pressure increased64.4
Osteomyelitis fungal52.3

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Flucytosine is on its molecule page.

Molecular formulaC4H4FN3O
Molecular weight129.09 g/mol
CAS number2022-85-7
InChIKeyXRECTZIEBJDKEO-UHFFFAOYSA-N
PubChem CID3366
NC1=NC(=O)NC=C1F

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Flucytosine used for?

DrugCentral lists the following indications for Flucytosine: Candidal Urinary Tract Infection, Synergy for Candida Infection, Synergy for Cryptococcal Infection, Systemic Candidiasis Treatment Adjunct and Systemic Cryptococcosis Treatment Adjunct.

How does Flucytosine work?

Its molecular targets in DrugCentral include HSP82, HTR2A, TMP1 (inhibitor) and TMP1 (inhibitor).

When was Flucytosine first approved?

Flucytosine was first approved by the FDA in 1971.

What drug class does Flucytosine belong to?

Flucytosine is in the Nucleoside Analog Antifungal class.

What is the chemical formula of Flucytosine?

Flucytosine has the molecular formula C4H4FN3O and a molecular weight of 129.09 g/mol.

Browse: all drugs starting with F · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFP
First approval1971-11-26
AgencyFDA
Targets4
Indications5
FormulaC4H4FN3O
DrugCentral ID1188
Interactive profile